FDA approved Novartis Cosentyx as the first new biologic treatment for hidradenitis suppurativa patients in a decade
On Oct. 31, 2023, Novartis announced that the US Food and Drug Administration (FDA) had approved Cosentyx (secukinumab)…
On Oct. 31, 2023, Novartis announced that the US Food and Drug Administration (FDA) had approved Cosentyx (secukinumab)…